SCHEMBL10139833

SCHEMBL10139833

COc1ccc2nc(-c3n[nH]c(-c4ccc(C#N)cc4)c3O)[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
TP53 P04637 3/20 0.48
HPGD P15428 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 2/20 0.48
PKM P14618 2/20 0.48
LMNA P02545 1/20 0.48
AURKA O14965 1/20 0.48
KDR P35968 1/20 0.48
RAB9A P51151 3/20 0.47
KDM4E B2RXH2 2/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CHEK2 O96017 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20307758 0.87 NPC1 (0.52) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL10139834 0.83 CHEK2 (0.59) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL7976096 0.82 CHEK2 (0.54) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL10139818 0.82 KDM4E (0.55) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL7973859 0.80 NPC1 (0.53) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL10139817 0.78 KMT2A (0.48) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL10139787 0.78 KDM4E (0.58) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL10172741 0.77 F9 (0.53) CHEK2DGAT1SOAT1KCNH2PKN1
SCHEMBL7969419 0.74 F9 (0.52) NPC1TP53HPGDKMT2AALDH1A1
SCHEMBL7978212 0.73 F9 (0.65) NPC1TP53HPGDKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 NPC1 1029/4885TP53 4367/4885HPGD 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.